Aurinia Pharmaceuticals Stock Forecast
NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 2:22 PM ET
AUPH analyst consensus
Consensus (1 analysts)
none
Avg. price target
$17.86+10.01%
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 1 Wall Street analyst covering Aurinia Pharmaceuticals (2026-10-08), 0 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $17.86, with a high estimate of $21.00 and a low estimate of $16.00. The average target implies upside of 10.0% from the current price of $16.24.
The spread between the highest and lowest targets is 31.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for AUPH.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 0 | 0% |
| Hold | 1 | 100% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $16.00 | -1.45% |
| Average target | $17.86 | +10.01% |
| High target | $21.00 | +29.35% |